Patents by Inventor Gabriel A. Kwong
Gabriel A. Kwong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11977074Abstract: The invention relates to methods and products associated with in vivo enzyme profiling. In particular, biomarker nanoparticles capable of quantitatively detecting enzymatic activity in vivo are described. These nanoparticles can be used to detect in vivo enzyme activity. The invention also relates to products, kits, and databases for use in the methods of the invention.Type: GrantFiled: November 22, 2019Date of Patent: May 7, 2024Assignee: Massachusetts Institute of TechnologyInventors: Sangeeta N. Bhatia, David K. Wood, Gabriel A. Kwong, Andrew David Warren, Kevin Y. Lin
-
Publication number: 20230390335Abstract: Disclosed are synthetic antigen chimeric antigen receptor systems and methods of their use for the treatment of cancer.Type: ApplicationFiled: October 14, 2021Publication date: December 7, 2023Inventors: Gabriel Kwong, Marielena Gamboa, Ali Zamat, Ji-Ho Park, Heegon Kim, Phillip J. Santangelo, Daryll A. Vanover
-
Patent number: 11802303Abstract: Systems and methods for multiplexed cell sorting are provided herein. The disclosed cell sorting system is referred to as DNA gated sorting (DGS). An exemplary system provides a set of orthogonal sorting probes and release probes for sorting cells of one or more different cell types from a biological specimen.Type: GrantFiled: February 7, 2019Date of Patent: October 31, 2023Assignee: Georgia Tech Research CorporationInventors: Gabriel A. Kwong, Shreyas N. Dahotre
-
Patent number: 11732009Abstract: A nanoparticle activity sensor containing a reporter and at least one tuning domain that modifies a distribution or residence time of the activity sensor when administered to a patient. When administered to the patient, the activity sensor enters cells or tissue where it is cleaved by enzymes specific to a physiological state such as a disease to release a detectable analyte. The tuning domains include molecular structures that modulate distribution or decay by protecting the particle from premature cleavage and indiscriminate hydrolysis, shielding the particle from immune detection and clearance, or by targeting the particle to specific tissue, bodily fluids, or cell types.Type: GrantFiled: March 15, 2019Date of Patent: August 22, 2023Assignee: GLYMPSE BIO, INC.Inventors: Sangeeta Bhatia, Gabriel Kwong, Eric Huang, Sirshendu Roopom Banerjee, Andrew Warren, Sophie Cazanave
-
Patent number: 11703510Abstract: The present invention relates to methods and products associated with in vivo enzyme profiling. In particular, the invention relates to methods of in vivo processing of exogenous molecules followed by detection of signature molecules as representative of the presence of active enzymes associated with diseases or conditions. The invention also relates to products, kits, and databases for use in the methods of the invention.Type: GrantFiled: November 6, 2020Date of Patent: July 18, 2023Assignee: Massachusetts Institute of TechnologyInventors: Sangeeta N. Bhatia, Geoffrey A. von Maltzahn, Gabriel A. Kwong
-
Publication number: 20230194544Abstract: The present invention relates to methods and products associated with in vivo enzyme profiling. In particular, the invention relates to methods of in vivo processing of exogenous molecules followed by detection of signature molecules as representative of the presence of active enzymes associated with diseases or conditions. The invention also relates to products, kits, and databases for use in the methods of the invention.Type: ApplicationFiled: November 18, 2022Publication date: June 22, 2023Applicant: Massachusetts Institute of TechnologyInventors: Sangeeta N. Bhatia, Geoffrey A. von Maltzahn, Gabriel A. Kwong
-
Publication number: 20230121144Abstract: It is an object of this disclosure to provide systems, devices, and methods for the direct use of fluorescent reporters that measure multiaxial and dynamic shear flows that occur invitro or in vivo across a surface of interest, where shear flows canbe measured, quantified and/or correlated to physiological changes in cells or tissues in real time. In certain embodiments, this disclosure contemplates imaging or visualizing the shear field applied to a surface, e.g., a surface of cells or inner lining of a blood vessel, the lumen of pumping lymphatics, within the bile duct, vessels with significant leakage, inflamed endothelium, tumor vasculature, or other systems.Type: ApplicationFiled: March 12, 2021Publication date: April 20, 2023Inventors: David Myers, Yonggang Ke, Victor Pan, Shreyas Dahotre, Gabriel Kwong
-
Publication number: 20230111954Abstract: Some aspects of this invention provide reagents and methods for the sensitive, quantitative and simultaneous detection of target analytes in complex biological samples by liquid chromatography tandem mass spectrometry (LC MS/MS). Some aspects of this invention provide affinity reagents encoded with mass reporters for the sensitive and quantitative translation of an analyte of interest into a mass tag. The reagents and methods provided herein have general utility in analyte detection and encoding, for example, in biomolecular profiling, molecular diagnostics, and biochemical encoding.Type: ApplicationFiled: December 8, 2022Publication date: April 13, 2023Applicant: Massachusetts Institute of TechnologyInventors: Gabriel A. Kwong, Sangeeta N. Bhatia
-
Patent number: 11549947Abstract: Some aspects of this invention provide reagents and methods for the sensitive, quantitative and simultaneous detection of target analytes in complex biological samples by liquid chromatography tandem mass spectrometry (LC MS/MS). Some aspects of this invention provide affinity reagents encoded with mass reporters for the sensitive and quantitative translation of an analyte of interest into a mass tag. The reagents and methods provided herein have general utility in analyte detection and encoding, for example, in biomolecular profiling, molecular diagnostics, and biochemical encoding.Type: GrantFiled: December 14, 2017Date of Patent: January 10, 2023Assignee: Massachusetts Institute of TechnologyInventors: Gabriel A. Kwong, Sangeeta N. Bhatia
-
Patent number: 11549951Abstract: The present invention relates to methods and products associated with in vivo enzyme profiling. In particular, the invention relates to methods of in vivo processing of exogenous molecules followed by detection of signature molecules as representative of the presence of active enzymes associated with diseases or conditions. The invention also relates to products, kits, and databases for use in the methods of the invention.Type: GrantFiled: January 7, 2022Date of Patent: January 10, 2023Assignee: Massachusetts Institute of TechnologyInventors: Sangeeta N. Bhatia, Geoffrey A. von Maltzahn, Gabriel A. Kwong
-
Publication number: 20220404349Abstract: The present disclosure relates to methods and products associated with in vitro and in vivo protease activity measurements and enzyme profiling. Some aspects of the present disclosure relate to measuring remotely triggered protease activity. In particular, the disclosure relates to methods of in vivo processing of exogenous molecules followed by detection of signature molecules as representative of the presence or absence of active enzymes associated with disease or conditions. The disclosure also relates to products, kits, and databases for use in the methods of the disclosure.Type: ApplicationFiled: July 20, 2022Publication date: December 22, 2022Applicant: Massachusetts Institute of TechnologyInventors: Sangeeta N. Bhatia, Gabriel A. Kwong, Piyush K. Jain, Jaideep S. Dudani, Simone Schurle
-
Publication number: 20220381781Abstract: CRISPR-based diagnostic methods and compositions are provided. One embodiment provides the use of DNA-barcoded antibodies or peptide-MHC (pMHC) tetramers (e.g., Kb-OVA257-264, Db-GP10025-33, Db-GP33-41) and CRISPR-Cas protein, and a guided DNA endonuclease, to achieve ultrasensitive detection of soluble and cell surface proteins. The disclosed embodiments can use type V: Cas12a; type VI: Cas13a, or Cas13b. Combining DNA encoding with CRISPR-Cas protein recognition is a sensitive system because barcodes can be isothermally amplified and Cas, for example Cas12a, enzymatically cleaves DNA reporters upon barcode detection, providing two rounds of amplification and enabling measurement of protein concentration by sample fluorescence or using by paper-based assays.Type: ApplicationFiled: October 16, 2020Publication date: December 1, 2022Applicant: GEORGIA TECH RESEARCH CORPORATIONInventors: Gabriel A. KWONG, Shreyas DAHOTRE, Yun Min CHANG, Adrian HARRIS, Fang-Yi SU
-
Patent number: 11428689Abstract: The present disclosure relates to methods and products associated with in vitro and in vivo protease activity measurements and enzyme profiling. Some aspects of the present disclosure relate to measuring remotely triggered protease activity. In particular, the disclosure relates to methods of in vivo processing of exogenous molecules followed by detection of signature molecules as representative of the presence or absence of active enzymes associated with disease or conditions. The disclosure also relates to products, kits, and databases for use in the methods of the disclosure.Type: GrantFiled: May 5, 2017Date of Patent: August 30, 2022Assignee: Massachusetts Institute of TechnologyInventors: Sangeeta N. Bhatia, Gabriel A. Kwong, Piyush K. Jain, Jaideep S. Dudani, Simone Schurle
-
Publication number: 20220249369Abstract: Disclosed herein are protease-based biological circuits for use in the diagnosis and treatment of disease and disorders characterized by aberrant protease signaling. An exemplary method of treating disease in a subject includes administering to the subject a plurality of therapeutic agent loaded-liposomes, wherein each of the liposomes comprises a different density of peptides surrounding the core and a different dose of the therapeutic agent, wherein the peptides comprise a cleavage site for a protease of interest, and wherein cleavage of the peptides open the liposome and release the therapeutic agent from within the liposome.Type: ApplicationFiled: September 19, 2019Publication date: August 11, 2022Applicant: GEORGIA TECH RESEARCH CORPORATIONInventors: Brandon HOLT, Gabriel KWONG
-
Publication number: 20220185889Abstract: Compositions and methods for pharmacodynamic monitoring of immunotherapy are provided herein. The compositions include an immunotherapeutic agent linked to protease substrates. Upon administration, the compositions target to sites of disease where proteases are upregulated during responsive immunotherapy and subsequently cleave the attached substrates. Cleavage fragments are detected in a sample from the body and detection of the fragments is indicative of an effect of the immunotherapeutic agent.Type: ApplicationFiled: September 11, 2019Publication date: June 16, 2022Inventors: James Bowen, Gabriel Kwong, Quoc Mac
-
Publication number: 20220186285Abstract: An activity-based nanosensor composition for detecting protease activity comprising a cleavable detectable substrate and methods of use are disclosed.Type: ApplicationFiled: January 13, 2022Publication date: June 16, 2022Inventors: Gabriel A. Kwong, Andrew B. Adams, Quoc Mac, David V. Mathews
-
Publication number: 20220181034Abstract: Disclosed herein are bacterial protease-activated prodrug compositions and methods of their use for the treatment and prevention of bacterial infection. Also disclosed are methods of reducing or eliminating defiant bacterial populations. An exemplary prodrug composition includes a cationic antimicrobial peptide conjugated to an anionic peptide with a protease cleavable linker substrate, wherein the antimicrobial peptide is inactive while it is in conjugation with the anionic peptide. Upon cleavage by the protease, the cationic AMP is released from the anionic peptide and can act upon bacteria. The protease is specific to the bacteria that are present in the sample or the subject, creating an auto-titrating mechanism wherein the AMP is released from the peptide only when there is bacteria present.Type: ApplicationFiled: September 19, 2019Publication date: June 9, 2022Applicant: GEORGIA TECH RESEARCH CORPORATIONInventors: Brandon HOLT, Gabriel KWONG
-
Publication number: 20220128571Abstract: The present invention relates to methods and products associated with in vivo enzyme profiling. In particular, the invention relates to methods of in vivo processing of exogenous molecules followed by detection of signature molecules as representative of the presence of active enzymes associated with diseases or conditions. The invention also relates to products, kits, and databases for use in the methods of the invention.Type: ApplicationFiled: January 7, 2022Publication date: April 28, 2022Applicant: Massachusetts Institute of TechnologyInventors: Sangeeta N. Bhatia, Geoffrey A. von Maltzahn, Gabriel A. Kwong
-
Publication number: 20220090162Abstract: Methods and compositions for screening or diagnosis of liver disease are provided. The results may also indicate course and efficacy of treatment. The composition includes an activity sensor and a reporter releasably attached to the activity sensor. The method includes detecting the presence and/or amount of a reporter. The reporter is released from an activity sensor in the presence of diseased liver tissue but remains attached to the activity sensor in healthy tissue. The presence and/or amount of the reporter are used to characterize the liver disease. The liver disease may be nonalcoholic steatohepatitis (NASH) and results may further indicate staging of NASH.Type: ApplicationFiled: June 4, 2021Publication date: March 24, 2022Inventors: Sangeeta Bhatia, Gabriel Kwong, Eric Huang, Sirshendu Roopom Banerjee, Andrew Warren, Sophie Cazanave
-
Patent number: 11028425Abstract: Methods and compositions for screening or diagnosis of liver disease are provided. The results may also indicate course and efficacy of treatment. The composition includes an activity sensor and a reporter releasably attached to the activity sensor. The method includes detecting the presence and/or amount of a reporter. The reporter is released from an activity sensor in the presence of diseased liver tissue but remains attached to the activity sensor in healthy tissue. The presence and/or amount of the reporter are used to characterize the liver disease. The liver disease may be nonalcoholic steatohepatitis (NASH) and results may further indicate staging of NASH.Type: GrantFiled: March 15, 2019Date of Patent: June 8, 2021Assignee: GLYMPSE BIO, INC.Inventors: Sangeeta Bhatia, Gabriel Kwong, Eric Huang, Sirshendu Roopom Banerjee, Andrew Warren, Sophie Cazanave